SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 11, 2004
------------------
DRAGON PHARMACEUTICAL INC.
(Exact Name of Registrant as Specified in Charter)
Florida 0-27937 65-0142474
(State or Other Jurisdiction of (Commission File Number) (IRS Employer
Incorporation) Identification No.)
1055 Hastings Street, Suite 1900 V6E 2E9
Vancouver, British Columbia (Zip Code)
(Address of Principal Executive Offices)
Registrant's telephone number, including area code: (604) 669-8817
N/A
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events and Regulation FD Disclosure
On June 14, 2004, Dragon Pharmaceutical, Inc. ("Dragon") announced that it
had executed a Share Purchase Agreement with Oriental Wave Holding Ltd., a
company incorporated under the laws of the British Virgin Islands ("Oriental
Wave") and the shareholders of Oriental Wave dated June 11, 2004. Under the
Share Purchase Agreement, Dragon will purchase all of Oriental Wave's shares in
consideration for the issuance of shares of common stock of Dragon. The
acquisition of Oriental Wave is subject to a number of conditions, including the
approval by Dragon's shareholders of the issuance of Dragon's shares of common
stock to the Oriental Wave shareholders.
Oriental Wave is a private company and through its wholly-owned subsidiary,
Shanxi Weiqida Pharmaceutical Co., Ltd., is engaged in the production of
chemical intermediates and active pharmaceutical ingredients and the
formulation, marketing and sale of generic drugs. Assuming the acquisition is
completed, Oriental Wave will become a wholly-owned subsidiary of Dragon and the
current Oriental Wave shareholders will own approximately 68.35% of Dragon.
A copy of the June 14, 2004 press release is attached as an exhibit.
Item 7. Financial Statements and Exhibits
Exhibit No. Exhibit Description
---------- -------------------
10.16 Share Purchase Agreement Among Dragon Pharmaceutical,
Inc., Oriental Wave Holding Ltd., and Yan-Lin Han,
Zhan Guo-Weng and Xue-Mei Liu.
99.1 Press release announcing agreement with Oriental Wave
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DRAGON PHARMACEUTICAL INC.
Date: June 21, 2004 By: /s/ Matthew Kavanagh
----------------------------------
Name: Matthew Kavanagh
Title: Director of Finance and Compliance
(Principal Financial and Accounting
Officer)